Search

Search Constraints

You searched for: Author/Creator Anton, Angelyn

Search Results

1. Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. Issue 6 (30th January 2022)

2. Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting. Issue 2 (13th April 2021)

4. Impact of access to novel therapies on the initial management of castrate‐resistant prostate cancer: an Australian multicentre study. Issue 11 (11th November 2019)

5. Molecular classification of hormone‐sensitive and castration‐resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. Issue 9 (18th April 2022)

6. Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer. (30th November 2022)

7. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?. (7th February 2023)

8. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. (November 2021)

9. Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer. Issue 3 (14th December 2021)

10. Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer. Issue Volume 128:Issue Supplement 1(2021) (7th October 2021)